AstraZeneca commits to at least 400 million doses of University of Oxford potential COVID-19 vaccine

After reaching a landmark agreement with the University of Oxford today for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from SARS-CoV-2, AstraZeneca have now committed to at least 400 million doses. 

It is planned that the first shipments will begin rolling out to the U.K. in September, then the United States in October. The company does not intend to stop there, though. It has already secured a total manufacturing capacity for 1 billion doses of the vaccine and intends to engage further agreements that will expand global capacity over the coming months.

The effort has been supported by more than $1 billion from the U.S. Biomedical Advanced Research and Development Authority (BARDA), which will be put toward development, production, and delivery of the vaccine beginning in the fall. Part of that process includes a 30,000 participant Phase III clinical trial, along with a pediatric trial. Phase 1 and 2 clinical trials to assess safety, immunogenicity, and efficacy in more than 1,000 healthy volunteers began last month. The next trials will be run in parallel with scaled manufacturing at BARDA’s Centers for Innovation and Advanced Development in Manufacturing.


Our Current Sponsors